277 related articles for article (PubMed ID: 15988670)
1. [Epidemiology and costs of diabetes mellitus in Germany].
Hauner H
Dtsch Med Wochenschr; 2005 Jul; 130 Suppl 2():S64-5. PubMed ID: 15988670
[No Abstract] [Full Text] [Related]
2. [Diabetes care in sub-Saharan Africa].
Labie D
Med Sci (Paris); 2007 Mar; 23(3):320-2. PubMed ID: 17349296
[No Abstract] [Full Text] [Related]
3. Diabetes costs rise, but so does adherence.
Manag Care; 2005 Apr; 14(4):54. PubMed ID: 15898213
[No Abstract] [Full Text] [Related]
4. [Costs of the treatment of hyperglycemia in patients with diabetes mellitus. The impact of age, type of therapy and complications: results of the German CoDiM study].
von Ferber L; Köster I; Hauner H
Med Klin (Munich); 2006 May; 101(5):384-93. PubMed ID: 16685485
[TBL] [Abstract][Full Text] [Related]
5. Diabetes--prevalence and cost of illness in Germany: a study evaluating data from the statutory health insurance in Germany.
Stock SA; Redaelli M; Wendland G; Civello D; Lauterbach KW
Diabet Med; 2006 Mar; 23(3):299-305. PubMed ID: 16492214
[TBL] [Abstract][Full Text] [Related]
6. [Diabetes mellitus--high costs, good prospects].
Heinzl S
Med Monatsschr Pharm; 2006 Mar; 29(3):83. PubMed ID: 16550879
[No Abstract] [Full Text] [Related]
7. Epidemiology and costs of diabetes treated with insulin in France.
Detournay B; Raccah D; Cadilhac M; Eschwège E
Diabetes Metab; 2005 Jun; 31(3 Pt 2):3-18. PubMed ID: 16142041
[TBL] [Abstract][Full Text] [Related]
8. [Insulin analogues--which dimension should be discussed?].
Verspohl EJ
Med Monatsschr Pharm; 2006 Jun; 29(6):198-9. PubMed ID: 16792195
[No Abstract] [Full Text] [Related]
9. Trends in the prescription and cost of diabetic medications and monitoring equipment in England 1991-2004.
Patel H; Srishanmuganathan J; Car J; Majeed A
J Public Health (Oxf); 2007 Mar; 29(1):48-52. PubMed ID: 17124257
[TBL] [Abstract][Full Text] [Related]
10. [Epidemiology of diabetes in metropolitan France].
Ricordeau P; Weill A; Vallier N; Bourrel R; Fender P; Allemand H
Diabetes Metab; 2000 Sep; 26 Suppl 6():11-24. PubMed ID: 11011236
[TBL] [Abstract][Full Text] [Related]
11. Resource utilisation and costs in patients with type 2 diabetes mellitus treated with insulin glargine or conventional basal insulin under real-world conditions in Germany: LIVE-SPP study.
Schöffski O; Breitscheidel L; Benter U; Dippel FW; Müller M; Volk M; Pfohl M
J Med Econ; 2008; 11(4):695-712. PubMed ID: 19450076
[TBL] [Abstract][Full Text] [Related]
12. [Costs of antihyperglycemic drugs and consumables and treatment satisfaction in patients with type 2 diabetes. Results of the health care research study LIVE-DE (long-acting insulin glargine compared with NPH insulin in Germany)].
Hauner H; Kohlmann T; Landgraf W; Holle R; Pirk O; Scholten T
Dtsch Med Wochenschr; 2009 Jun; 134(23):1207-13. PubMed ID: 19472091
[TBL] [Abstract][Full Text] [Related]
13. Comment and reply on: Relative efficacy/effectiveness and relative costs of treatment with insulin glargine and insulin detemir.
Freemantle N; Stella P; Munro V
Curr Med Res Opin; 2007 Aug; 23(8):1761-2; author reply 1762-4. PubMed ID: 17588305
[No Abstract] [Full Text] [Related]
14. The future of diabetes technologies and therapeutics.
Jones M; Harrison JM
Diabetes Technol Ther; 2002; 4(3):351-9. PubMed ID: 12165175
[No Abstract] [Full Text] [Related]
15. ["The Lantus case": and yet it does move (or not?)].
Schöffski O
Dtsch Med Wochenschr; 2010 Sep; 135(36):1755-6. PubMed ID: 20812163
[No Abstract] [Full Text] [Related]
16. [Reduced neuropathic risk via enhanced glucose control?].
Ziegler D
Dtsch Med Wochenschr; 2013 Mar; 138(11):513. PubMed ID: 23463469
[No Abstract] [Full Text] [Related]
17. Rising Costs of Drug/Insulin Treatment for Diabetes: A Perspective from India.
Misra A; Mukherjee R; Luthra A; Singh P
Diabetes Technol Ther; 2017 Dec; 19(12):693-698. PubMed ID: 29090974
[No Abstract] [Full Text] [Related]
18. [Are the short-acting insulin analogs superfluous?].
Arand M
MMW Fortschr Med; 2006 Mar; 148(11):17. PubMed ID: 16612957
[No Abstract] [Full Text] [Related]
19. The cost-effectiveness of insulin glargine vs. neutral protamine Hagedorn insulin in type 2 diabetes: a focus on health economics.
Levin P
Diabetes Obes Metab; 2008 Jul; 10 Suppl 2():66-75. PubMed ID: 18577158
[TBL] [Abstract][Full Text] [Related]
20. Diabetes in Africa. Challenges to health care for diabetes in Africa.
Whiting DR; Hayes L; Unwin NC
J Cardiovasc Risk; 2003 Apr; 10(2):103-10. PubMed ID: 12668907
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
